Exchange: NASDAQ·Updated 01:54 PM EDT
REGN logo

REGNRegeneron Pharmaceuticals, Inc.

$642.86
$18.14
(2.90%)
Today
EarningsJul 30
Mkt Cap$65.5B
Vol406,248.00
News
all
press releases
Why Regeneron (REGN) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks
News Placeholder
More News
News Placeholder
What Sparked the $43B Jump in AbbVie's Market Cap in the Past Week?
ABBV surged nearly 11% in a week as acquisitions, new approvals and pipeline expansion strengthen confidence in its long-term growth strategy.
Zacks
News Placeholder
Is Regeneron Pharmaceuticals, Inc. (REGN) Among the Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds?
Is Regeneron Pharmaceuticals, Inc. (REGN) Among the Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds...
Yahoo! Finance: News
News Placeholder
Here's Why You Should Add Kiniksa Stock to Your Portfolio Now
KNSA's Arcalyst sales continue to grow as raised 2026 revenue guidance and an expanding IL-1 pipeline reinforce Kiniksa's growth strategy.
Zacks
News Placeholder
BAYRY Stock Surges 17% After Supreme Court Roundup Ruling
Bayer shares jump 17% after a Supreme Court ruling on Roundup litigation that could significantly reduce warning-based claims and litigation costs.
Zacks
News Placeholder
Regeneron's Applications for gMG Drug Accepted by FDA and EMA
Regeneron's cemdisiran won FDA Priority Review and EMA filing acceptance for gMG, backed by phase III data and a potentially unique dosing schedule.
Zacks
News Placeholder
ABBV Jumps on Deepening Immunology Portfolio With $10.9B APGE Buyout
AbbVie shares jump after its $10.9B Apogee deal adds late-stage eczema and respiratory candidates, deepening its immunology pipeline.
Zacks
News Placeholder
Can Sanofi Rely on Dupixent to Drive Long-Term Revenue Growth?
SNY's Dupixent is expanding into new diseases and geographies, strengthening its position as a key driver of long-term revenue growth.
Zacks
News Placeholder
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years
read more...
Benzinga
News Placeholder
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up
Immuneering stock rises after dosing the first patient in a pivotal phase III study of atebimetinib plus mGnP for first-line metastatic pancreatic cancer.
Zacks
<
1
2
...
>

Advertisement|Remove ads.